Patienterne, der fik radioaktivt mærket Zevalin, overlevede gennemsnitligt i 37 måneder, inden deres sygdom forværredes, sammenlignet med 14 måneder for dem, som ikke fik nogen supplerende behandling.
Patients receiving radiolabelled Zevalin survived for an average of 37 months until their disease got worse, compared with 14 months in those who did not receive any further treatment.